《新股消息》鷹瞳科技(02251.HK)公開發售超購5.2倍及下限定價 一手中籤率15.55%
醫療器械公司鷹瞳科技(02251.HK)公布招股結果,每股發售價定為75.1元,為下限定價(招股價介乎75.1元至至81.3元)。香港公開發售部分錄得超額認購約5.18倍,每手100股計,中籤率為15.55%,要認購7手即700股才可穩獲一手。該股將於明日(5日)掛牌,瑞銀及中信證券為聯席保薦人。
基石投資者合共認購719.87萬股,佔緊隨全球發售完成後公司已發行股本約7%,當中CloudAlpha認購155.37萬股,廣發基金認購103.58萬股,常春藤認購72.5萬股等。
公司預計,是次上市集資淨額約15.66億元,約50%擬用作分配予核心產品Airdoc-AIFUNDUS的持續優化、開發及商業化;約19%用於資助硬件設備的研發及生產;約10%用於資助正在進行的及未來的健康風險評估解決方案的研發;約6%用於產品組合的開發,以豐富人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案;約5%用於為公司與學術及研究機構就聯合研究項目進行的合作提供資金;及約10%用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.